# First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks

> **NCT01555125** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 177 (actual)

## Conditions studied

- Moderate to Severe Plaque-type Psoriasis

## Interventions

- **DRUG:** secukinumab 150 mg
- **DRUG:** secukinumab 300 mg
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01555125
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05-08
- **Primary completion:** 2016-10-24
- **Final completion:** 2016-10-24
- **Target enrollment:** 177 (ACTUAL)
- **Last updated:** 2018-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01555125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01555125, "First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01555125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*